No Country for Alzheimer’s Patients

Biden’s CMS refuses Medicare coverage despite evidence of treatment progress.

In an interview with 'Global View' columnist Walter Russell Mead, the Prime Minister of Israel pointed to developments in Iran, then queried what might happen should it become the first nuclear power run by radical Islam. The answer, he says, is to "expand the circle of peace." Images: Reuters/AP/AFP via Getty Images Composite: Mark Kelly

President Biden says his Administration is leading the fight against Alzheimer’s disease, but at the same time it is restricting access to breakthrough treatments. Members of Congress in both parties and Alzheimer’s experts are calling out this contradiction.

The Centers for Medicare and Medicaid Services (CMS) took the unprecedented step last year of limiting coverage of novel Alzheimer’s drugs. Normally if the Food and Drug Administration approves a drug, Medicare pays for it. But CMS said it wasn’t convinced that a new class of Alzheimer’s drugs is “reasonable and necessary” for seniors.

Opinion

Continue reading your article with
a WSJ subscription

Subscribe Now

Already a member? Sign In

Sponsored Offers